Shots: Amgen has consummated the purchase of Astellas’49% shares of AABP, a JV between Amgen and Astellas established in 2013 AABP now serves as a wholly-owned Amgen affiliate in Japan while the Amgen renamed it as Amgen KK, enabling the company to bolster its presence in Japan Amgen KK will continue the marketing of therapies […]Read More
Shots: Astellas to receive ~$88.3M as up front for its three products. Daiichi to get rights and obligations, including manufacturing and marketing approvals for Nasea (ramosetron), Perdipine (nicardipine) and Oldeca (barnidipine) from Dec’2019 The focus of the agreement is to strengthen Daiichi’s presence in Asia and to contribute to healthcare in Asia by acquiring two […]Read More
Shots: Aronora to receive $6M upfront & $3M upon fulfillment of certain conditions. Xoma to get rights to royalties and 10% of milestone payments associated with five hematology assets from Aronora. The transaction is expected to close within the next 90 days The focus of the transaction is to expand XOMA’s portfolio with the addition […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
